Literature DB >> 21332551

Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage.

Byung Ik Kim1, Hong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Hong Soo Kim, Dong Joon Kim.   

Abstract

BACKGROUND AND AIM: There have been no trials comparing the prophylactic effect of oral quinolone and intravenous cephalosporin antibiotics and elucidating the predictive factors for the occurrence of bacterial infections in cirrhotic patients with gastrointestinal bleeding in Asian-Pacific region.
METHODS: One hundred and thirteen patients with advanced liver cirrhosis and active gastrointestinal hemorrhage were enrolled in our study. The patients were randomly allocated into either the oral ciprofloxacin group (n = 50, 500 mg every 12 h) or the intravenous ceftriaxone group (n = 63, 2.0 g per day for 7 days).
RESULTS: Proven or possible infections were significantly more frequent in the patients in the oral ciprofloxacin group (34.0%) than the intravenous ceftriaxone group (14.3%, P = 0.002). The intestinal permeability index (IPI, mean [SD]) measured the day after admission was significantly higher in the patients with proven or possible infections (1.45 [0.96]) compared with the no infection group (0.46 [0.48], P <0.01). By multivariate analysis, oral ciprofloxacin prophylaxis and higher IPI at the time of inclusion were independent and significant predictors for proven or possible infections. By receiver operating characteristic curve analysis, the best cutoff value of IPI for the prediction of the occurrence of bacterial infection was 0.62%.
CONCLUSIONS: The frequency of proven or possible infections was significantly lower in the intravenous ceftriaxone group compared with the oral ciprofloxacin group. The IPI measured the day after admission is a good clinical parameter predicting the occurrence of infection in these patients.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21332551     DOI: 10.1111/j.1440-1746.2010.06490.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  13 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 2.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

3.  Evidence that intra-amniotic infections are often the result of an ascending invasion - a molecular microbiological study.

Authors:  Roberto Romero; Nardhy Gomez-Lopez; Andrew D Winters; Eunjung Jung; Majid Shaman; Janine Bieda; Bogdan Panaitescu; Percy Pacora; Offer Erez; Jonathan M Greenberg; Madison M Ahmad; Chaur-Dong Hsu; Kevin R Theis
Journal:  J Perinat Med       Date:  2019-11-26       Impact factor: 1.901

Review 4.  Gastrointestinal dysfunction in liver cirrhosis.

Authors:  Evangelos Kalaitzakis
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

5.  Prophylaxis for Stress Ulcers With Proton Pump Inhibitors Is Not Associated With Increased Risk of Bloodstream Infections in the Intensive Care Unit.

Authors:  Margot E Cohen; Joanne M Hathway; Hojjat Salmasian; Jianfang Liu; Melissa Terry; Julian A Abrams; Daniel E Freedberg
Journal:  Clin Gastroenterol Hepatol       Date:  2017-01-18       Impact factor: 11.382

Review 6.  Changes of Intestinal Functions in Liver Cirrhosis.

Authors:  Hiroshi Fukui; Reiner Wiest
Journal:  Inflamm Intest Dis       Date:  2016-03-08

7.  Acute Variceal Bleed in Cirrhosis is Associated With Reversible Changes in Tight Junction Protein Expression in the Intestine: A Proof-of-Concept Study.

Authors:  Kanav Kaushal; Vipin Gupta; Pooja Goswami; Samagra Agarwal; Sanchit Sharma; Prasenjit Das; Rajni Yadav; Abhinav Anand; Ujjwal Sonika; Deepak Gunjan; Anoop Saraya
Journal:  J Clin Exp Hepatol       Date:  2021-04-03

8.  The end-organ impairment in liver cirrhosis: appointments for critical care.

Authors:  Antonio Figueiredo; Francisco Romero-Bermejo; Rui Perdigoto; Paulo Marcelino
Journal:  Crit Care Res Pract       Date:  2012-05-16

Review 9.  Intestinal permeability in a patient with liver cirrhosis.

Authors:  Jonathan Manuel Aguirre Valadez; Liliana Rivera-Espinosa; Osvely Méndez-Guerrero; Juan Luis Chávez-Pacheco; Ignacio García Juárez; Aldo Torre
Journal:  Ther Clin Risk Manag       Date:  2016-11-18       Impact factor: 2.423

Review 10.  Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure.

Authors:  Cornelius Engelmann; Thomas Berg
Journal:  Visc Med       Date:  2018-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.